טוען...
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review
BACKGROUND: . Teriflunomide is an immunomodulatory drug approved for Multiple Sclerosis (MS) treatment that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in the de novo pyrimidine synthesis pathway. This mechanism can produce antiviral effects, thus teriflunomide has gained...
שמור ב:
| הוצא לאור ב: | Mult Scler Relat Disord |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier B.V.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7836732/ https://ncbi.nlm.nih.gov/pubmed/33429305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102734 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|